Table 2.
Secondary hemostasis screening tests, coagulation, fibrinolytic and inhibitory proteins.
| Characteristics | Patients (n = 32) | Controls (n = 15) | Normal Range | |
|---|---|---|---|---|
| Pre-HD | Post-HD | |||
| Secondary hemostasis screening test | ||||
| aPTT (s) | 56.7 ± 32.1 ** | 35.5 ± 7.0 **# | 29.7 ± 3.7 | <36 |
| D-Dimers (µg/L) | 661.2 ± 438.6 ** | 694.8 ± 425.3 ** | 272.7 ± 140.2 | <500 |
| Fibrinogen (mg/dL) | 411.8 ± 92.4 ** | 464.5 ± 112.7 **# | 328.4 ± 79.6 | 180–350 |
| PT/INR | 1.4 ± 0.7 ** | 1.2 ± 0.4 **# | 0.98 ± 0.04 | <1.2 |
| Coagulation system | ||||
| Factor II (%) | 79.0 ± 19.3 ** | 81.4 ± 21.4 ** | 107.9 ± 13.2 | 60–120 |
| Factor V (%) | 85.7 ± 23.6 ** | 106.0 ± 19.2 # | 104.9 ± 17.2 | 60–120 |
| Factor VII (%) | 105.9 ± 37.0 | 110.8 ± 39.2 | 116.0 ± 19.8 | 60–120 |
| Factor VIII (%) | 148.8 ± 79.9 | 247.1 ± 85.5 **# | 123.3 ± 17.6 | 60–140 |
| Factor IX (%) | 115.2 ± 43.4 | 123.0 ± 39.9 | 115.9 ± 17.9 | 60–120 |
| Factor X (%) | 77.1 ± 27.0 | 82.0 ± 35.1 | 89.1 ± 15.8 | 60–120 |
| Factor XI (%) | 100.3 ± 49.6 | 121.3 ± 50.6 | 112.6 ± 16.1 | 60–120 |
| Factor XII (%) | 87.1 ± 24.2 ** | 108.1 ± 22.3 # | 109.9 ± 26.9 | 60–120 |
| Factor XIII (%) | 145.9 ± 12.1 ** | 149.8 ± 11.0 ** | 101.1 ± 11.9 | 60–140 |
| RiCof (%) | 160.6 ± 53.6 | 191.8 ± 72.4 **# | 122.7 ± 34.1 | 60–140 |
| vWF (%) | 170.4 ± 58.0 ** | 216.8 ± 74.7 **# | 110.0 ± 20.8 | 60–140 |
| Fibrinolytic system | ||||
| PAI (U/mL) | 1.9 ± 1.2 ** | 1.6 ± 1.1 ** | 0.8 ± 1.1 | <4 |
| Plasminogen (ng/L) | 100.5 ± 15.3 | 112.8 ± 17.4 **# | 108.1 ± 8.8 | 80–120 |
| Inhibitory system | ||||
| Antithrombin III (%) | 96.9 ± 13.8 ** | 105.6 ± 14.5 # | 122.3 ± 10.1 | 80–120 |
| Protein C (%) | 80.8 ± 18.8 ** | 91.6 ± 23.1 **# | 110.3 ± 14.5 | 70–140 |
| Protein S activity (%) | 89.6 ± 23.3 | 99.3 ± 33.9 | 91.9 ± 16.5 | 60–130 |
| Protein Sf (%) | 95.6 ± 69.9 ** | 92.6 ± 27.4 **# | 109.1 ± 26.3 | 60–140 |
| ADAMTS-13 | ||||
| ADAMTS13 activity (%) | <5 ** | <5 ** | 57.3 ± 4.8 | 17–63 |
| ADAMTS13 Inhibitor (%) | 81.4 ± 25.1 ** | 86.6 ± 11.5 **# | 12.0 ± 5.0 | <30 |
Values are presented as mean ± SD. PT-INR, Prothrombin time—International Normalized Ratio; aPTT, Activated Partial Thromboplastin Time; RiCof, Platelet Ristocetin Cofactor; Protein Sf, Protein S Antigen free; PAI, Plasminogen Activator Inhibitor; ADAMTS, A Disintegrin, and Metalloproteinase with Thrombospondin motifs. Bold: pathological values, ** p < 0.01 vs. controls, # p < 0.05 pre- vs. post-HD.